These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1350502)

  • 41. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
    Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
    Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in eye tracking during clinical stabilization in schizophrenia.
    Rea MM; Sweeney JA; Solomon CM; Walsh V; Frances A
    Psychiatry Res; 1989 Apr; 28(1):31-9. PubMed ID: 2568005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment.
    Kaneda Y; Jayathilak K; Meltzer H
    Psychiatry Res; 2010 Jun; 178(1):57-62. PubMed ID: 20452677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Double-blind study of clozapine dose response in chronic schizophrenia.
    Simpson GM; Josiassen RC; Stanilla JK; de Leon J; Nair C; Abraham G; Odom-White A; Turner RM
    Am J Psychiatry; 1999 Nov; 156(11):1744-50. PubMed ID: 10553738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
    Volavka J; Nolan KA; Kline L; Czobor P; Citrome L; Sheitman B; Lindenmayer JP; McEvoy J; Lieberman JA
    Schizophr Res; 2005 Jul; 76(1):127-9. PubMed ID: 15927808
    [No Abstract]   [Full Text] [Related]  

  • 47. Subjective response to neuroleptics in schizophrenia.
    Awad AG
    Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroleptic-resistant schizophrenia treated with clozapine and ECT.
    Benatov R; Sirota P; Megged S
    Convuls Ther; 1996 Jun; 12(2):117-21. PubMed ID: 8744173
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clozapine treatment after agranulocytosis induced by classic neuroleptics.
    Bauer M; Mackert A
    J Clin Psychopharmacol; 1994 Feb; 14(1):71-3. PubMed ID: 7908676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.
    Kronig MH; Munne RA; Szymanski S; Safferman AZ; Pollack S; Cooper T; Kane JM; Lieberman JA
    Am J Psychiatry; 1995 Feb; 152(2):179-82. PubMed ID: 7840349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Presentation of obsessive-compulsive symptoms in a patient with schizophrenia treated with clozapine].
    Stengler-Wenzke K
    Psychiatr Prax; 1999 May; 26(3):145-6. PubMed ID: 10412713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.
    Lieberman JA; Safferman AZ; Pollack S; Szymanski S; Johns C; Howard A; Kronig M; Bookstein P; Kane JM
    Am J Psychiatry; 1994 Dec; 151(12):1744-52. PubMed ID: 7977880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Postpsychotic depression" and residual schizophrenia in a mental health hospital.
    Mauri MC; Laini V; Barone R; Clemente A; Volonteri LS; Cerveri G; Steinhilber C; Fornier M
    Encephale; 2000; 26(6):21-6. PubMed ID: 11217534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel neuroleptics in schizophrenia: theory and clinical relevance.
    Remington GJ
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S43-5. PubMed ID: 7533050
    [No Abstract]   [Full Text] [Related]  

  • 56. Low dose medication strategies in the maintenance treatment of schizophrenia.
    Kane JM
    Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
    Potkin SG; Jin Y; Bunney BG; Costa J; Gulasekaram B
    Am J Psychiatry; 1999 Jan; 156(1):145-7. PubMed ID: 9892314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
    Fleischhaker C; Schulz E; Remschmidt H
    Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aripiprazole in treatment-refractory schizophrenia.
    Hsu WY; Lee CI; Chiu NY; Kahn DA
    J Psychiatr Pract; 2009 May; 15(3):221-6. PubMed ID: 19461396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Defining treatment refractoriness in schizophrenia.
    Brenner HD; Dencker SJ; Goldstein MJ; Hubbard JW; Keegan DL; Kruger G; Kulhanek F; Liberman RP; Malm U; Midha KK
    Schizophr Bull; 1990; 16(4):551-61. PubMed ID: 1981813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.